-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Upstream Bio, Lowers Price Target to $50

Benzinga·05/14/2026 12:56:55
Listen to the news
Mizuho analyst Joseph Catanzaro maintains Upstream Bio (NASDAQ:UPB) with a Outperform and lowers the price target from $51 to $50.